التفاصيل البيبلوغرافية
| العنوان: |
Nefrotik sendromlu çocukların böbrek biyopsi örneklerinde Sphingomiyelin phosphodiesterase acid-like 3b (SMPDL-3b) ekspresyonu immunsüpresif ilaç cevabında yol gösterici olabilir mi |
| المؤلفون: |
Kaya, Muhammet |
| المساهمون: |
GiriÅŸgen, Ä°lknur |
| بيانات النشر: |
Pamukkale Üniversitesi Tıp Fakültesi |
| سنة النشر: |
2022 |
| المجموعة: |
Pamukkale University Repository / Pamukkale Üniversitesi Açık Erişim Arşivi |
| مصطلحات موضوعية: |
Nefrotik sendrom, SMPDL-3b, rituksimab, Real time PCR, Nephrotic syndrome, rituximab, real-time PCR |
| الوصف: |
Bu çalışma Pamukkale Üniversitesi Bilimsel Araştırma Projeleri Koordinasyon Birimi’nin 16/01/2020 tarih ve 1 nolu kararı ile desteklenmiştir ; Objective: Idiopathic nephrotic syndrome (INS) is a common glomerular disease in children. Although INS usually responds to steroids, patients with frequently relapse or steroid dependence face adverse effects associated with long-term steroid use. Some patients who develop steroid-resistant nephrotic syndrome (SRNS) are also resistant to other immunosuppressants and can progress to chronic kidney disease (CKD). The treatment of SRNS remains a challenge for pediatric nephrologists.Rituximab is a CD20 monoclonal antibody shown to be successful in the treatment of frequently relapsing and steroid-dependent NS, but its effectiveness in patients with SRNS or focal segmental glomerulosclerosis (FSGS) has varied between studies. Sphingomyelin phosphodiesterase acid-like 3b (SMPDL-3b) contributes to the regulation of the podocyte cytoskeleton by enabling ceramide synthesis in the cell membrane. Recent studies suggest that rituximab prevents proteinuria independent of B-cell depletion by inhibiting the downregulation of SMPDL-3b expression or binding to SMPDL-3b. However, the question remains whether the low amount of SMPDL-3b for rituximab to bind in treatment-resistant NS patients with advanced podocyte injury could be the cause of treatment resistance. Based on the limited number of studies related to rituximab and SMPDL-3b, the present study was conducted to evaluate whether SMPDL-3b level in pre-treatment kidney biopsy is predictive of the clinical effectiveness of immunosuppressive drugs, especially rituximab, in patients with SRNS and FSGS. Methods: Kidney biopsy specimens from 48 patients diagnosed with INS in our clinic were analyzed by immunohistochemical staining with anti-SMPDL3B and real-time polymerase chain reaction (PCR) for SMPDL-3b mRNA expression. The results were compared according to treatment response. Real time PCR evaluation was done with 2-??CT ... |
| نوع الوثيقة: |
other/unknown material |
| اللغة: |
Turkish |
| Relation: |
Tez; https://hdl.handle.net/11499/45769 |
| الاتاحة: |
https://hdl.handle.net/11499/45769 |
| Rights: |
open |
| رقم الانضمام: |
edsbas.3E9D1F75 |
| قاعدة البيانات: |
BASE |